Home > Research Areas > Cancer > Colon Cancer
Cat. No. Product name CAS No.
DC4231 Linifanib (ABT-869)

ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families.

796967-16-3
DC10371 Anlotinib

Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1,which can be used to treat non-small cell lung cancer.

1058156-90-3
DC2088 CI-1040 (PD184352)

CI-1040 (PD 184352) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM.

212631-79-3
DC11107 CKD-516

CKD-516 (Valecobulin, CKD516) is a potent beta-tubulin polymerization inhibitor with marked antitumor activity both in vitro and in vivo.

1188371-47-2
DC7902 Fruquintinib (HMPL-013)

Fruquintinib (HMPL-013) is a novel small molecule compound that selectively inhibits vascular endothelial growth factor receptors (VEGFRs).

1194506-26-7
DC8247 KNK437

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.

218924-25-5
DC7186 LGK-974

LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM.

1243244-14-5
DC10099 BGB283

Lifirafenib(BGB-283) is a Novel potent and selective RAF Kinase and EGFR inhibitor.

1446090-77-2
DC7465 MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

1032350-13-2
DC9682 ML-264

ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5).

1550008-55-3
DC8474 Napabucasin (BBI608)

Napabucasin (BBI608) is an orally-administered small molecule which can block cancer stem cell (CSC) self-renewal and induces cell death in CSCs as well as non-stem cancer cells.

83280-65-3
DC9770 NCB-0846

NCB-0846 is a novel,first-in-class,orally TNIK inhibitor with an IC50 value of 21 nM,that have shown strong anti-tumor efficacy against several cancer models.

1792999-26-8
DC9777 Regorafenib monohydrate(BAY 73-4506)

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

1019206-88-2
DC1030 Regorafenib (BAY73-4506,Fluoro-Sorafenib)

Regorafenib (BAY 73-4506, Fluoro-Sorafenib) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

755037-03-7
DC7078 AZD-8931(Sapitinib)

Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively.

848942-61-0
DC7283 SCH-772984

SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 of 4 nM and 1 nM, respectively.

942183-80-4
Page 1 / Total 1 FirstPrevNextLastGoto